Wedbush Keeps Their Buy Rating on Xoma Corp (XOMA)

By Jason Carr

In a report released today, Liana Moussatos from Wedbush reiterated a Buy rating on Xoma Corp (XOMAResearch Report), with a price target of $25. The company’s shares closed yesterday at $15.99.

According to TipRanks.com, Moussatos ‘ ranking currently consits of no stars on a 0-5 ranking scale, with an average return of -12.8% and a 26.9% success rate. Moussatos covers the Healthcare sector, focusing on stocks such as BioMarin Pharmaceutical Inc., Allena Pharmaceuticals Inc, and Aquestive Therapeutics Inc.

Xoma Corp has an analyst consensus of Moderate Buy, with a price target consensus of $27.50, representing a 72.0% upside. In a report released yesterday, H.C. Wainwright also reiterated a Buy rating on the stock with a $30 price target.

See today’s analyst top recommended stocks >>

The company has a one-year high of $24.01 and a one-year low of $11.02. Currently, Xoma Corp has an average volume of 84.17K.

Based on the recent corporate insider activity of 13 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of XOMA in relation to earlier this year.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

XOMA Corp. engages in the discovery and development of innovative therapeutics derived from platform of antibody technologies. Its products includes X358, X213, X129, and gevokizumab. The company was founded by Patrick J. Scannon in 1981 and is headquartered in Emeryville, CA.